AstraZeneca shells out up to $60M to reserve more coronavirus shot capacity with Oxford Biomedica

AstraZeneca will pay Oxford Biomedica an initial $20 million to reserve 1,000 liters of production capacity for its adenovirus-based COVID-19 vaccine, AZD1222, for at least 18 months, the companies said Monday. AstraZeneca is developing the shot with Oxford University.